Market Cap (In KRW)
158.98 Billion
Revenue (In KRW)
13.82 Billion
Net Income (In KRW)
-55.42 Billion
Avg. Volume
1.41 Million
- Currency
- KRW
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 1489.0-3235.0
- PE
- -
- EPS
- -
- Beta Value
- -1.104
- ISIN
- KR7205470008
- CUSIP
- -
- CIK
- -
- Shares
- 113153831.0
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Medical - Equipment & Services
- CEO
- Sung-gon Kim
- Employee Count
- -
- Website
- http://www.humasis.com
- Ipo Date
- 2017-09-27
- Details
- Humasis Co. Ltd. develops, manufactures, and markets in-vitro diagnostics for the detection of cardiac marker, fertility hormone, infectious disease, tumor marker, and cotinine for home and laboratory use in South Korea and internationally. It offers pregnancy and ovulation self-test products; Hubi-Quan Pro, a self-contained and cartridge reader to provide rapid quantitative results for membrane-based lateral flow immunochromatographic assays; and various rapid test kits. The company was founded in 2000 and is based in Anyang, South Korea.
More Stocks
-
CANFINHOMECan Fin Homes Limited
CANFINHOME
-
8053
-
NFYEFNFI Group Inc.
NFYEF
-
6536Tiga Gaming Inc.
6536
-
TG
-
GOLDENTOBCGolden Tobacco Limited
GOLDENTOBC
-
ENAKFE.ON SE
ENAKF
-
GRCO